Aldeyra Therapeutics (ALDX) shares got a boost on Tuesday after the company announced positive results for its NS2. NS2 traps and eliminates aldehydes, which are suspected to be "toxic mediators in numerous diseases." NS2 supports the activity of an enzyme called aldehyde dehydrogenases, whose job it is to eliminate aldehydes from the body. NS2 works very rapidly, within hours, trapping aldehydes, transporting them to lysosomes (which contain degraded enzymes in eukaryotic cells), and eliminating them from the body. In in vitro and preclinical models, NS2 demonstrated its ability to trap free aldehydes, and in murine and 3d skin models it has diminished inflammation, reduced healing time, protected lipid and other key cellular constituents from aldehyde damage, and reduced scarring. In a report last year, I had noted that ALDX has a fair value of $18.70 per share. I continue to believe that ALDX is an attractive takeover target.

Valeant Pharmaceuticals (VRX) shares surged on Tuesday as investors digested the company’s Q2 results. While VRX posted yet another loss, it noted the steps it plans to take to get back on track. VRX said that it would reorganize and sell some of its noncore assets in order to bring down its debt levels. VRX also reaffirmed its financial guidance for 2016, which has eased concerns of triggering a debt-covenant breach. I continue to believe that VRX’s market capitalization is significantly below the value of its assets. If the company remains on track with its restructuring we could continue to see a recovery.

Mylan Reports Q2 Results- Mylan (MYL) reported its second-quarter financial results on Tuesday, logging an 8% growth in sales. The company’s profit for the quarter came in at $168.4 million, or $0.33 per share. This compares to $167.8 million, or $0.32 per share reported for the same period in the previous year. Excluding one-time items, MYL reported earnings of $1.16 per share, compared to 91 cents reported for the same period last year. Revenue rose to $2.56 billion. More important, MYL backed its full-year outlook.

Array BioPharma Plunges As Selumetinib Fails- AstraZeneca (AZN) announced that its experimental drug selumetinib failed to meet its goal in a late-stage trial for lung cancer. The outcome was expected though after the drug had failed in another study for treating a rare cancer of the eye in July 2015.

The news sent ARRY shares down more than 22% on Tuesday. AZN had acquired exclusive worldwide rights to selumetinib from ARRY, which has received $26.5M in up-front and milestone payments and is entitled to ~$70M in potential additional development milestone payments and royalties on product sales.

Endo Soars on Q2 Results- Endo International (ENDP) shares were among the biggest gainers in the biotech sector on Tuesday after the company’s second-quarter earnings and revenue beat consensus forecast. ENDP’s generic drug sales rose 67% on a year-over-year basis. Overall, revenue jumped 25% on a year-over-year basis. For 2016, ENDP reaffirmed its guidance. The company expects earnings to be between $4.50 per share and $4.80 per share, compared to consensus forecast of $4.54 per share. Full year revenue is expected to be between $3.87 billion and $4.03 billion, compared to consensus forecast of $3.93 billion.

No approvals to report.

No patents to report.

No deals and collaborations to report.

No secondary offerings to report.

No IPOs to report.

BioDelivery Sciences (BDSI) reported a loss of $0.31 per share in its second quarter, in-line with the consensus forecast. The company’s revenue for the quarter was $5 million, up 189% on a year-over-year basis. Revenue beat consensus forecast by $1.65 million.

Aeglea BioTherapeutics (AGLE) reported a loss of $0.46 per share in its second quarter. The company reported revenue of $1.37 million, down 60.1% on a year-over-year basis.

Cellular Biomedicine (CBMG) reported a loss of $0.52 per share in its second quarter. The company reported revenue of $0.07 million, down 89.6% on a year-over-year basis.

Vical (VICL) reported a loss of $0.14 per share in its second quarter, beating consensus forecast by 14 cents. The company reported revenue of $4.12 million, down 1.4% on a year-over-year basis. Revenue missed consensus forecast by $0.37 million.

Sage Therapeutics (SAGE) reported a loss of $1.08 per share in its second quarter, missing consensus forecast by 6 cents. The company ended the quarter with $189 million in cash and cash equivalents on its balance sheet.

Bellerophon Therapeutics (BLPH) reported a loss of $0.39 per share in its second quarter, beating consensus forecast by 12 cents. The company ended the quarter with $1.3 million in cash and cash equivalents on its balance sheet.

Syndax Pharmaceuticals (SNDX) reported a loss of $0.47 per share in its second quarter. The company reported revenue of $0.31 million, up 1450% on a year-over-year basis.

Eagle Pharmaceuticals (EGRX) reported earnings of $0.80 per share in its second quarter, beating consensus forecast by 9 cents. The company reported revenue of $40.92 million, up 582% on a year-over-year basis. Revenue beat consensus forecast by $0.12 million.

Concert Pharma (CNCE) reported a loss of $0.60 per share in its second quarter, beating consensus forecast by 3 cents. The company reported revenue of $0.07 million, down 99.9% on a year-over-year basis. Revenue beat consensus forecast by $0.04 million.

Incyte (INCY) reported earnings of $0.18 per share in its second quarter, beating consensus forecast by 20 cents. The company reported revenue of $246.29 million, up 51.1% on a year-over-year basis. Revenue beat consensus forecast by $11.05 million.

Alliqua Biomedical (ALQA) reported a loss of $0.19 per share in its second quarter, beating consensus forecast by 8 cents. The company reported revenue of $5.5 million, up 77.4% on a year-over-year basis. Revenue beat consensus forecast by $0.12 million.

Impax Lab (IPXL) reported earnings of $0.21 per share in its second quarter, missing consensus forecast by 11 cents. The company reported revenue of $172.59 million, down 19.4% on a year-over-year basis. Revenue missed consensus forecast by $51.08 million.

Titan Pharmaceuticals (TTNP) reported earnings of $0.58 per share in its second quarter, beating consensus forecast by 2 cents. The company reported revenue of $15 million, in-line with the consensus forecast.

Ionis Pharmaceuticals (IONS) reported a loss of $0.47 per share in its second quarter, beating consensus forecast by 5 cents. The company reported revenue of $38.47 million, down 68.1% on a year-over-year basis. Revenue missed consensus forecast by $0.05 million.

Antares Pharma (ATRS) reported second-quarter loss of $0.04 per share, in-line with the consensus forecast. The company reported revenue of $12.23 million, down 15.2% on a year-over-year basis. Revenue beat consensus forecast by $1.23 million.

Blueprint Medicines (BPMC) reported a loss of $0.70 per share in its second quarter, beating consensus forecast by 3 cents. The company reported revenue of $7.07 million, up 162.8% on a year-over-year basis. Revenue beat consensus forecast by $2.66 million.

GTx (GTXI) reported a loss of $0.04 per share in its second quarter, beating consensus forecast by a penny.

GW Pharmaceuticals (GWPH) reported a loss of GBP 0.05 per share in its third quarter. Revenue for the quarter was GBP 2.34 million, down 72.9% on a year-over-year basis.

Selecta Biosciences (SELB) reported a loss of $2.75 per share in its second quarter. The company reported revenue of $2.02 million, up 62.9% on a year-over-year basis.

Nabriva Therapeutics (NBRV) reported a loss of $5.64 per share in its second quarter. The company ended the quarter with cash and cash equivalents of $36.4 million on its balance sheet.

Ocular Therapeutix (OCUL) reported a loss of $0.46 per share in its second quarter, beating consensus forecast by 3 cents. The company reported revenue of $0.44 million, down 4.3% on a year-over-year basis. Revenue missed consensus forecast by $0.11 million.

Derma Sciences (DERM) reported earnings of $0.08 per share in its second quarter, beating consensus forecast by 16 cents. The company reported revenue of $22.21 million, down 1.6% on a year-over-year basis. Revenue missed consensus forecast by $0.19 million.

Amicus Therapeutics (FOLD) reported a loss of $0.40 per share in its second quarter, missing consensus forecast by 7 cents. The company ended the quarter with $63.7 million in cash and cash equivalents on its balance sheet.

AMAG Pharmaceuticals (AMAG) reported earnings of $1.45 per share in its second quarter, beating consensus forecast by 25 cents. The company reported revenue of $127.42 million, up 2.9% on a year-over-year basis. Revenue missed consensus forecast by $1.1 million.

Aralez Pharmaceuticals (ARLZ) reported a loss of $0.27 per share in its second quarter, missing consensus forecast by 5 cents. The company reported revenue of $12.58 million, up 141.9% on a year-over-year basis. Revenue beat consensus forecast by $0.65 million.

Mast Therapeutics (MSTX) reported a loss of $0.05 per share in its second quarter, beating consensus forecast by a penny. The company ended the quarter with $35.07 million in cash and equivalents on its balance sheet.

Stellar Biotechnologies (SBOT) reported a loss of $0.14 per share in its third quarter, missing consensus forecast by 2 cents. The company reported revenue of $0.18 million, up 5.9% on a year-over-year basis. Revenue missed consensus by $0.52 million.

Galectin Therapeutics (GALT) reported a loss of $0.20 per share in its second quarter, beating consensus forecast by 4 cents. The company ended the quarter with $18 million in non-restricted cash and cash equivalents.

Cancer Genetics (CGIX) reported a loss of $0.28 per share in its second quarter, beating consensus forecast by 5 cents. The company reported revenue of $7 million, up 67.5% on a year-over-year basis. Revenue beat consensus forecast by $0.5 million.

Axsome Therapeutics (AXSM) reported a loss of $0.36 per share in its second quarter. The company ended the quarter with $38.8 million in cash and equivalents on its balance sheet.

Fortress Biotech (FBIO) reported a loss of $0.31 per share in its second quarter. The company reported revenue of $2.2 million.

Marinus Pharmaceuticals (MRNS) reported a loss of $0.46 per share in its second quarter, missing consensus forecast by 8 cents. The company ended the quarter with $39.1 million in its cash and cash equivalents on its balance sheet.

Provectus Biopharmaceuticals (PVCT) reported a loss of $0.02 per share in its second quarter. The company ended the quarter with $4.89 million in cash and equivalents on its balance sheet.

Puma Biotechnology (PBYI) reported a loss of $2.05 per share in its second quarter, beating consensus forecast by 13 cents. The company ended the quarter with $57.8 million in cash and cash equivalents on its balance sheet.

Elite Pharmaceuticals (ELTP) broke even in its first quarter. The company reported revenue of $3.3 million, up 51.4% on a year-over-year basis.

ARCA Biopharma (ABIO) reported a loss of $0.43 per share in its second quarter. The company ended the quarter with $31.4 million in cash and equivalents on its balance sheet.

Aegerion Pharmaceuticals (AEGR) reported a loss of $0.72 per share in its second quarter, missing consensus forecast by 12 cents. The company reported revenue of $44.5 million, down 30.7% on a year-over-year basis. Revenue beat consensus forecast by $9 million.

Adverum Biotechnologies (ADVM) reported a loss of $1.76 per share in its second quarter. The company’s revenue for the quarter was $0.31 million, up 55% on a year-over-year basis. Revenue beat consensus forecast by $0.11 million.

Ignyta (RXDX) reported a loss of $0.70 per share in its second quarter, missing consensus forecast by 5 cents. The company ended the quarter with cash and equivalents of $174.6 million on its balance sheet.

OpGen (OPGN) reported a loss of $0.37 per share in its second quarter. The company reported revenue of $1.18 million, up 210.5% on a year-over-year basis.

Acura Pharmaceuticals (ACUR) reported a loss of $0.28 per share in its second quarter. The company reported revenue of $0.26 million, down 23.5% on a year-over-year basis.

REGENXBIO (RGNX) reported a loss of $0.55 per share in its second quarter. The company reported revenue of $2.38 million, up 75% on a year-over-year basis.

MyoKardia (MYOK) reported a loss of $0.37 per share in its second quarter. The company reported revenue of $3.55 million, flat on a year-over-year basis.

Anthera Pharmaceuticals (ANTH) reported a loss of $0.35 per share in its second quarter, missing consensus forecast by 4 cents. The company ended the quarter with $28.5 million in cash and cash equivalents on its balance sheet.

Repros Therapeutics (RPRX) reported a loss of $0.18 per share in its second quarter, beating consensus forecast by 2 cents. The company ended the quarter with $12.5 million in cash and cash equivalents on its balance sheet.

Sophiris (SPHS) reported a loss of $0.21 per share in its second quarter. The company ended the quarter with $8.3 million in cash and equivalents on its balance sheet.

Catalyst Pharmaceutical (CPRX) reported a loss of $0.06 per share in its second quarter, beating consensus forecast by 2 cents. The company ended the quarter with $48 million in cash and cash equivalents, ertificates of deposit and short-term investments.
Coherus Bioscience (CHRS) reported a loss of $1.72 per share in its second quarter, missing consensus forecast by 40 cents. The company reported revenue of $14.07 million, up 104.8% on a year-over-year basis.

Immune Design (IMDZ) reported a loss of $0.71 per share in its second quarter, missing consensus forecast by 3 cents. The company reported revenue of $1.13 million, down 36.5% on a year-over-year basis. Revenue missed consensus forecast by $0.72 million.

Calithera Biosciences (CALA) reported a loss of $0.55 per share in its second quarter, missing consensus forecast by 3 cents. The company ended the quarter with $60.4 million in cash, cash equivalents and investments on its balance sheet.

Cardiome Pharma (CRME) reported a loss of $0.37 per share in its second quarter, missing consensus forecast by 18 cents. The company reported revenue of $5.9 million, up 2.8% on a year-over-year basis. Revenue missed consensus forecast by $0.83 million.

Ohr Pharmaceutical (OHRP) reported a loss of $0.24 per share in its third quarter, beating consensus forecast by 3 cents. The company ended the quarter with $17.6 million in cash and cash equivalents on its balance sheet.

CymaBay Therapeutics (CBAY) reported a loss of $0.30 per share in its second quarter, beating consensus forecast by 2 cents. The company ended the quarter with $29.1 million in cash, cash equivalents and short-term investments on its balance sheet.
Editas Medicine (EDIT) reported a loss of $0.54 per share in its second quarter. The company’s revenue for the quarter was $3.4 million.

Arrowhead Pharmaceuticals (ARWR) reported a loss of $0.32 per share in its third quarter, beating consensus forecast by 5 cents. The company’s revenue for the quarter was $0.04 million, down 66.7% on a year-over-year basis. Revenue missed consensus forecast by $0.02 million.

Omeros (OMER) reported a loss of $0.32 per share in its second quarter, beating consensus forecast by 18 cents. The company’s revenue for the quarter was $10 million, up 213.5% on a year-over-year basis. Revenue beat consensus forecast by $0.76 million.

Arcadia Biosciences (RKDA) reported a loss of $0.10 per share in its second quarter, missing consensus forecast by 3 cents. The company reported revenue of $0.72 million, down 49.7% on a year-over-year basis. Revenue missed consensus forecast by $1.18 million.

Jazz Pharmaceuticals (JAZZ) reported earnings of $2.63 per share in its second quarter, missing consensus forecast by 17 cents. The company reported revenue of $381.2 million, up 14.2% on a year-over-year basis. Revenue beat consensus forecast by $4.78 million.

Novavax (NVAX) reported a loss of $0.29 per share in its second quarter, missing consensus forecast by 4 cents. The company reported revenue of $2.5 million, down 82.1% on a year-over-year basis. Revenue missed consensus forecast by $5.53 million.

Galena Biopharma (GALE) reported earnings of $0.03 per share in its second quarter, beating consensus forecast by 9 cents. The company ended the quarter with $19.6 million in cash and cash equivalents on its balance sheet.

Aeterna Zentaris (AEZS) reported a loss of $0.71 per share in its second quarter, beating consensus forecast by 11 cents. The company reported revenue of $0.1 million for the quarter, down 50% on a year-over-year basis. Revenue missed consensus forecast by $0.65 million.

Caladrius Biosciences (CLBS) reported a loss of $1.33 per share in its second quarter, beating consensus forecast by 40 cents. The company’s revenue for the quarter was $8.3 million, up 41.4% on a year-over-year basis. Revenue beat consensus forecast by $0.77 million.

Medivation (MDVN) reported earnings of $0.29 per share in its second quarter, beating consensus forecast by 2 cents. The company’s revenue for the quarter was $206.2 million, up 17.4% on a year-over-year basis. Revenue missed consensus forecast by $6.54 million.

SciClone Pharmaceuticals (SCLN) reported earnings of $0.20 per share in its second quarter. The company reported revenue of $39 million, up 2.9% on a year-over-year basis.
Codexis (CDXS) reported earnings of $0.12 per share in its second quarter, beating consensus forecast by 9 cents. The company reported revenue of $16 million, up 165.8% on a year-over-year basis. Revenue beat consensus forecast by $0.9 million.

OncoMed (OMED) reported a loss of $0.91 per share in its second quarter, missing consensus forecast by 10 cents. The company reported revenue of $6.7 million, up 42.9% on a year-over-year basis. Revenue missed consensus forecast by $1.39 million.

BioTime (BTX) reported earnings of $0.26 per share in its second quarter. The company reported revenue of $1.3 million, down 35% on a year-over-year basis.

Portola Pharmaceuticals (PTLA) reported a loss of $1.02 per share in its second quarter. The company’s loss was 18 cents below the consensus forecast. PTLA’s revenue for the quarter was $4.2 million, up 76.5% on a year-over-year basis. Revenue missed consensus forecast by $0.18 million.

Intrexon (XON) reported a loss of $0.42 per share in its second quarter. The company’s revenue for the quarter was $52.5 million, up 17% on a year-over-year basis. Revenue missed consensus forecast by $1.28 million.

Tobira (TBRA) reported a loss of $0.71 per share in its second quarter, missing consensus forecast by 8 cents. The company reported revenue of $1.1 million, beating consensus forecast by $1.05 million.

Aptose Biosciences (APTO) reported a loss of $0.46 per share in its second quarter, missing consensus forecast by 18 cents. The company ended the quarter $12.6 million in cash and cash equivalents on its balance sheet.

Zogenix (ZGNX) reported a loss of $0.76 per share in its second quarter, beating consensus forecast by 5 cents. The company reported revenue of $2.1 million, down 71.5% on a year-over-year basis. Revenue missed consensus forecast by $3.26 million.
Spectrum Pharmaceuticals (SPPI) reported a loss of $0.05 per share in its second quarter, beating consensus forecast by 24 cents. The company reported revenue of $33.9 million, down 24.6% on a year-over-year basis. Revenue beat consensus forecast by $3.02 million.

Halozyme Therapeutics (HALO) reported a loss of $0.21 per share in its second quarter, beating consensus forecast by 6 cents. The company reported revenue of $33.3 million, down 23.2% on a year-over-year basis. Revenue beat consensus forecast by $3.36 million.

ZIOPHARM Oncology (ZIOP) reported a loss of $1.01 per share in its second quarter. The company reported revenue of $1.7 million, beating consensus forecast by $0.18 million.

Athresys (ATHX) reported a loss of $0.08 per share in its second quarter, beating consensus forecast by 2 cents. The company reported revenue of $0.6 million, up 172.7% on a year-over-year basis. Revenue beat consensus forecast by $0.28 million.

BioSpecifics (BSTC) reported earnings of $0.35 per share in its second quarter, in-line with the consensus forecast. Revenue for the quarter was $6.2 million, up 31.6% on a year-over-year basis. Revenue beat consensus forecast by $0.28 million.

Company (Ticker) Brokerage Action Recommendation Price Target My Price Target
Abiomed (ABMD) Jefferies Group Price Target Raised Buy From $130 to $145 N/A
Abbott Laboratories (ABT) Deutsche Bank Reiterate Buy N/A N/A
Achillion Pharmaceuticals (ACHN) Jefferies Group Reiterate Hold N/A

$7.50

Affimed Therapeutics (AFMD) Jefferies Group Reiterate Hold N/A N/A
Allergan Plc (AGN) Royal Bank of Canada Price Target Cut Outperform From $307 to $300 N/A
Allergan Plc (AGN) Deutsche Bank Price Target Cut Buy From $282 to $278 N/A
Allergan Plc (AGN) Piper Jaffray Cos. Price Target Set Hold

$227

N/A
Agile Therapeutics (AGRX) Noble Financial Reiterate Buy N/A N/A
Achaogen (AKAO) Needham & Company Reiterate Hold N/A

$23

Akebia Therapeutics (AKBA) Credit Suisse Group Reiterate Hold

$8

N/A
Alere (ALR) BTIG Research Upgrade From Neutral to Buy N/A N/A
Alexion Pharmaceuticals (ALXN) Jefferies Group Reiterate Hold N/A N/A
Amphastar Pharmaceuticals (AMPH) Needham & Company Price Target Raised Buy From $20 to $22 N/A
Amphastar Pharmaceuticals (AMPH) BMO Capital Markets Price Target Raised Hold

$17

N/A
Amphastar Pharmaceuticals (AMPH) Jefferies Group Price Target Raised Buy From $16 to $19 N/A
Array BioPharma (ARRY) Piper Jaffray Cos. Price Target Set Buy

$7

N/A
Atara Biotherapeutics (ATRA) Jefferies Group Reiterate Buy

$25

N/A
Biogen (BIIB) Leerink Swann Reiterate Hold

$367

$420

Bellicum Pharmaceuticals (BLCM) Citigroup Upgrade From Neutral to Buy

$24

N/A
Bellicum Pharmaceuticals (BLCM) Jefferies Group Price Target Raised Buy

$22

N/A
Bellicum Pharmaceuticals (BLCM) Piper Jaffray Cos. Reiterate Buy N/A N/A
Bristol-Myers Squibb (BMY) Citigroup Price Target Cut Buy From $80 to $75 N/A
Blueprint Medicines Corp. (BPMC) Wedbush Reiterate Outperform

$41

N/A
Blueprint Medicines Corp. (BPMC) Cowen and Company Reiterate Buy N/A N/A
ChemoCentryx (CCXI) JPMorgan Chase Reiterate Buy

$11

Celgene (CELG) Jefferies Group Reiterate Buy N/A N/A
Celldex Therapeutics (CLDX) Wedbush Reiterate Neutral

$3

N/A
Clovis Oncology (CLVS) JPMorgan Chase Reiterate Hold

$13

N/A
Chimerix (CMRX) FBR & Co. Price Target Cut Market Perform From $9 to $8 N/A
Chimerix (CMRX) JPMorgan Chase Reiterate Hold

$7

N/A
Endo International (ENDP) BMO Capital Markets Reiterate Hold

$22

N/A
Endo International (ENDP) Leerink Swann Reiterate Hold

$22

N/A
Endo International (ENDP) Piper Jaffray Cos. Price Target Set Hold

$19

N/A
Endo International (ENDP) JPMorgan Chase Price Target Set Buy

$40

N/A
Enanta Pharmaceuticals (ENTA) JPMorgan Chase Price Target Cut Buy From $31 to $26 N/A
Epizyme (EPZM) HC Wainwright Reiterate Buy N/A N/A
Fate Therapeutics (FATE) HC Wainwright Reiterate Buy N/A N/A
FibroGen (FGEN) Credit Suisse Group Reiterate Buy

$37

$37

GW Pharmaceuticals (GWPH) Cantor Fitzgerald Price Target Cut Buy From $181 to $165 N/A
GW Pharmaceuticals (GWPH) Cowen and Company Reiterate Buy N/A N/A
Heron Therapeutics (HRTX) Cantor Fitzgerald Reiterate Buy N/A N/A
Horizon Pharma (HZNP) Citigroup Price Target Raised Neutral From $18 to $21 N/A
Horizon Pharma (HZNP) Brean Capital Reiterate Buy

$30

N/A
Infinity Pharmaceuticals (INFI) Wedbush Reiterate Neutral From $1 to $1.25 N/A
Inovio Pharmaceuticals (INO) Maxim Group Downgrade From Buy to Hold N/A N/A
Kite Pharma (KITE) Maxim Group Price Target Cut Buy From $87 to $77 N/A
Kite Pharma (KITE) Barclays Plc Price Target Raised Hold From $58 to $60 N/A
Kite Pharma (KITE) Mizuho Price Target Set Buy

$80

N/A
MannKind (MNKD) Piper Jaffray Cos. Reiterate Underwright

$0.10

N/A
MyoKardia (MYOK) Wedbush Reiterate Outperform

$22

N/A
Nabriva Therapeutics (NBRV) Wedbush Reiterate Outperform

$17

N/A
Opko Health (OPK) JPMorgan Chase Price Target Set Buy

$14

$20

Ultragenyx Pharmaceuticals (RARE) Credit Suisse Group Reiterate Buy

$101

N/A
Ultragenyx Pharmaceuticals (RARE) Wedbush Reiterate Outperform

$92

N/A
Ultragenyx Pharmaceuticals (RARE) Piper Jaffray Cos. Price Target Set Buy

$82

N/A
Ultragenyx Pharmaceuticals (RARE) Cowen and Company Reiterate Buy N/A N/A
SCYNEXIS (SCYX) Needham & Company Price Target Cut Buy From $16 to $10 N/A
SCYNEXIS (SCYX) WBB Securities Upgrade From Speculative Buy to Buy

$8

N/A
Theravance BioPharma (TBPH) Leerink Swann Reiterate Buy N/A N/A
Valeant Pharmaceuticals International (VRX) Rodman & Renshaw Price Target Cut Buy From $90 to $81 N/A

Opko Health (OPK)- Dr. Phillip Frost, CEO & Chairman, bought 10,000 shares at $10.21. The total value of the transaction was $102,140. Dr. Frost now owns 159,942,343 shares of OPK.

No insider sells to report.

No management changes and additions to report.

NYSE- Valeant Pharmaceuticals International (VRX) shares were among the major gainers on the NYSE. The stock closed 25.43% higher.

NASDAQ- Endo International (ENDP) shares were among the major gainers on the NASDAQ. The stock closed 21.83% higher. BioCryst Pharmaceuticals (BCRX) ended the day 18.14% higher. Bellicum Pharmaceuticals (BLCM) ended the day 16.60% higher. Impax Laboratories (IPXL) shares were among the major losers on the NASDAQ. The stock closed 23.41% lower. Array Biopharma (ARRY) ended the day 22.70% lower. Sage Therapeutics (SAGE) ended the day 13.19% lower.

Company (Ticker) Short Interest as a % of Float % Change Days to Cover
Macrocure (MCUR)

3.8%

-26.3%

3

MacroGenics (MGNX)

8.1%

-1.2%

14

Madrigal Pharmaceuticals (MDGL)

2.2%

17.9%

1

MannKind (MNKD)

25.9%

-3.3%

46

Marinus Pharmaceuticals (MRNS)

8.1%

156.8%

1

Mateon Therapeutics (MATN)

3.4%

-9.2%

12

MediciNova (MNOV)

12%

-4.8%

54

Medivation (MDVN)

1.8%

5.3%

2

MEI Pharma (MEIP)

0.7%

-8.6%

3

Meridian Biosciences (VIVO)

9.8%

-3.2%

18